Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : email@example.com
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|AT9283||AT-9283|AT 9283||ABL1 Inhibitor 6 Aurka Inhibitors 24 Aurkb Inhibitors 20 JAK2 Inhibitor 17 JAK3 Inhibitor 5||AT9283 is a dual inhibitor of JAK 2 and 3 kinases, Aurora kinases A and B, and has activity against Abl T315I (PMID: 19143567, PMID: 27905678).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Unknown unknown||Advanced Solid Tumor||not applicable||AT9283||Phase I||Actionable||In a Phase I clinical trial, AT9283 demonstrated safety and efficacy in patients with advanced solid tumors (PMID: 22015452).||22015452|
|Unknown unknown||acute leukemia||no benefit||AT9283||Phase Ib/II||Actionable||In a Phase I/II trial, AT9283 demonstrated tolerable toxicity but no clinical response in children with acute leukemia, although the trial failed to identify its primary endpoints due to poor recruitment and early termination (PMID: 27905678).||27905678|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status||Covered Countries||Other Countries|